Overexpression of lncRNAs HOTAIR and MALAT1 While Downexpression of lncRNA PANDA Predict the Resistance of Diffuse Large B‐Cell Lymphoma to R‐CHOP Chemoimmunotherapy

• Published in: International journal of laboratory hematology Vol. 47; no. 3; pp. 463 - 471
• Main Authors: Ahmed, Yara Mohamed, El‐Khazragy, Nashwa, Haroun, Riham Abdel‐Hamid, Fathy, Shadia Abdel‐Hamid
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.06.2025
• Subjects: Adult; Aged; Antibodies, Monoclonal, Murine-Derived - administration & dosage; Antibodies, Monoclonal, Murine-Derived - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers; Biomarkers, Tumor - genetics; Clinical trials; Cyclophosphamide - administration & dosage; Cyclophosphamide - therapeutic use; diffuse large B‐cell lymphoma; Down-Regulation; Doxorubicin - administration & dosage; Doxorubicin - therapeutic use; Drug Resistance, Neoplasm - genetics; Female; Gene Expression Regulation, Neoplastic - drug effects; HOTAIR; Humans; long noncoding RNA; Lymph nodes; Lymphatic system; Lymphoma; Lymphoma, Large B-Cell, Diffuse - diagnosis; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - genetics; Lymphoma, Large B-Cell, Diffuse - mortality; MALAT1; Male; Middle Aged; Non-coding RNA; PANDA; Patients; Prednisone - administration & dosage; Prednisone - therapeutic use; Prognosis; Reverse transcription; Rituximab; RNA, Long Noncoding - biosynthesis; RNA, Long Noncoding - genetics; R‐CHOP chemoimmunotherapy; Therapeutic targets; Vincristine - administration & dosage; Vincristine - therapeutic use; HOTAIR; long noncoding RNA; MALAT1; PANDA; diffuse large B‐cell lymphoma; R‐CHOP chemoimmunotherapy

ABSTRACT Background Long noncoding RNAs (lncRNAs) have emerged as key regulators of cancer; in addition, they have been identified as novel therapeutic targets and biomarkers for several cancers, including diffuse large B‐cell lymphoma (DLBCL). Methods A total of 75 DLBCL patients and 30 control sub...